Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Petros Grivas MD, PhD

Petros Grivas MD, PhD

Professor, Department of Medicine, Division of Medical Oncology; Clinical Director, Genitourinary Cancers Program, University of Washington; Professor, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington

Dr. Petros Grivas has published widely in highly esteemed peer-reviewed journals and has authored more than 240 articles and book chapters. He has been a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), ECOG-ACRIN, ESMO, International Bladder Cancer Network, Bladder Cancer Advocacy Network, among other prestigious professional organizations.

With a strong interest in designing and conducting innovative clinical trials, Dr. Grivas's professional interests also involve clinical and translational research on experimental therapeutics in genitourinary cancers via a molecular biology–based approach aiming to translate results into clinical trials. He is dedicated to exceptional patient care, leadership, mentoring/teaching trainees, community outreach, diversity, equity and inclusion.

Having received his medical degree and PhD in medical oncology from the University of Patras School of Medicine in Greece, Dr. Grivas came to the US for his internal medicine residency at Drexel University College of Medicine/Hahnemann University Hospital in Philadelphia. He completed a fellowship in hematology/oncology at the University of Michigan in 2013 and took part in the GME Scholars Health Care Administration and Leadership Program at Michigan between 2012 and 2014.

Disclosures

Consulting: Aadi Bioscience, AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb, CG Oncology Inc., Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, MSD, Mirati Therapeutics, Pfizer, PureTech, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC, UroGen. His institution has received grants from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, MSD, Mirati Therapeutics, Pfizer, QED Therapeutics.

Recent Contributions to PracticeUpdate:

  1. New and Upcoming Data on Adjuvant Treatment of Urothelial Cancer
  2. New Data on Antibody-Drug Conjugates and Other Novel Compounds for Second-Line Urothelial Carcinoma Treatment
  3. Role of Herpesvirus 8 (HHV-8) in Patients With Metastatic CRPC
  4. Efficacy of Maintenance Avelumab in Bladder Cancer Based on Number of Prior Chemotherapy Cycles
  5. Natural History of Untreated Non-Muscle Invasive Bladder Cancer
  6. Current Clinical Data on Antibody Drug Conjugates for Advanced Urothelial Cancer
  7. Subgroup Analysis From a Trial of Avelumab Maintenance for Advanced Urothelial Carcinoma
  8. New Data on Immunotherapy Plus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma
  9. Impact of Age and Performance Status on Outcomes With First-Line Pembrolizumab for Advanced Urothelial Carcinoma
  10. ASCO: Adjuvant Atezolizumab for High-Risk Muscle-Invasive Bladder Cancer

Most Read This Week

Recently Updated